Ubrelvy vs Austedo
A side-by-side look at two neurology medications advertised on TV. Informational only — not medical advice.
| US Ubrelvy | US Austedo | |
|---|---|---|
| Generic name | ubrogepant | deutetrabenazine |
| Drug class | CGRP Receptor Antagonist | VMAT2 Inhibitor |
| Treats | Acute migraine | Tardive dyskinesia, Huntington's chorea |
| Category | Neurology | Neurology |
| Manufacturer | AbbVie | Teva |
| Year approved | 2019 | 2017 |
| FDA warning | No boxed warning | Black box warning |
| Est. TV ad spend | $160M | $150M |
| Common side effects | Nausea, Drowsiness, Dry mouth | Depression and suicidal thoughts (Huntington's), Drowsiness, Fatigue, Dry mouth |
Frequently asked questions
Is Ubrelvy or Austedo better?
Neither is universally "better." Ubrelvy (ubrogepant) and Austedo (deutetrabenazine) are both used for neurology, but the right choice depends on your medical history, insurance and your doctor's guidance. This comparison is informational only.
What's the difference between Ubrelvy and Austedo?
Ubrelvy is a CGRP Receptor Antagonist made by AbbVie, while Austedo is a VMAT2 Inhibitor made by Teva. See the table above for a side-by-side breakdown.
Which one spends more on TV ads?
Ubrelvy has the larger estimated TV advertising budget of the two.